Ad
related to: gm2 ganglioside function in the brain cells of kidney- Recommended Dosage
Discover Appropriate Dosage
to Treat Patients
- Kidney Transplant
Treatment for Kidney
Transplant Immunosuppression
- Kidney Transplant Therapy
Read About How Treatment May
Fight Against Acute Rejection
- Storage & Handling
Learn to Properly Store and
Handle Treatment for Patients
- Recommended Dosage
Search results
Results From The WOW.Com Content Network
GM2-gangliosidosis, AB variant is a rare, autosomal recessive metabolic disorder that causes progressive destruction of nerve cells in the brain and spinal cord. Mutations in the GM2A gene cause AB variant. The GM2A gene provides instructions for making a protein called the GM2 activator.
GM2A is a lipid transfer protein that stimulates the enzymatic processing of gangliosides, and also T-cell activation through lipid presentation. This protein binds molecules of ganglioside GM2, extracts them from membranes, and presents them to beta- hexosaminidase A for cleavage of N-acetyl-D-galactosamine and conversion to GM3.
The HEXA gene is a protein encoding gene that codes for the lysosomal enzyme beta-hexosaminidase. This enzyme, combined with the GM2 activator protein, is responsible for the breakdown of ganglioside GM2 within the lysosome. Defects in the HEXA gene, however, prevent this degradation, leading to a buildup of toxins in brain and spinal cord cells.
The name ganglioside was first applied by the German scientist Ernst Klenk in 1942 to lipids newly isolated from ganglion cells of the brain. [1] More than 60 gangliosides are known, which differ from each other mainly in the position and number of NANA residues.
Tay–Sachs disease occurs when hexosaminidase A loses its ability to function. People with Tay–Sachs disease are unable to remove the GalNAc residue from the G M2 ganglioside, and as a result, they end up storing 100 to 1000 times more G M2 gangliosides in the brain than the unaffected person. Over 100 different mutations have been ...
This enzyme catalyses the formation of the gangliosides (i.e. sialic-acid-containing glycosphingolipids) GM2, GD2 and SM2 from GM3, GD3 and SM3, respectively. References [ edit ]
Signs and symptoms of GM2-gangliosidosis, AB variant are identical with those of infantile Tay–Sachs disease, except that enzyme assay testing shows normal levels of hexosaminidase A. [2] Infantile Sandhoff disease has similar symptoms and prognosis, except that there is deficiency of both hexosaminidase A and hexosaminidase B. Infants with this disorder typically appear normal until the age ...
In collaboration with Scott D. Larsen, Shayman's work has also been directed toward the identification of brain-penetrant glycolipid synthesis inhibitors for the treatment of Gaucher disease types 2 and 3, [17] GM2 gangliosidoses including Tay-Sachs and Sandhoff disease, and GM1 gangliosidosis. [18]